Trial Profile
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Interferon alpha-2b; Interferon alpha-2b; Ipilimumab
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms SWOG 1404
- 08 Feb 2024 Planned End Date changed from 11 Dec 2024 to 23 Jan 2025.
- 21 Sep 2021 Results of a pooled analysis (from the E1609 and S404 studies) to estimate the incidence of GSL as reported by trial investigators presented at the 46th European Society for Medical Oncology Congress
- 21 Sep 2021 Results assessing quality of life presented at the 46th European Society for Medical Oncology Congress.